非筋層浸潤性膀胱がん患者におけるササンリマブの研究 (CREST)
抗 PD-1 抗体である PF-06801591 とカルメット-ゲラン菌 (BCG 維持を伴うまたは伴わない BCG 誘導) と BCG (誘導高リスク、BCG ナイーブの非筋層浸潤性膀胱がんまたは PF-06801591 の参加者で、BCG 非反応性 NMIBC の参加者の単剤として
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B).
In Part A (enrollment closed), each participant was assigned to one of three study treatment groups.
- One group is given sasanlimab and BCG at the study clinic.
- The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only.
- The third group is given BCG only and will not receive sasanlimab.
In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor.
- Both groups will be given sasanlimab at the study clinic.
On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B. The decision to discontinue enrollment to Part B was not made for safety reasons.
調査の概要
詳細な説明
CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment
Phase 3 Design with two Cohorts. Cohort A consists of 3 study Arms (A, B and C) of BCG naive participants. Arms A and B consist of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. Cohort B consists of B1 and B2, which test PF-06801591 and include participants who have BCG unresponsive CIS (B1) or BCG unresponsive papillary only disease (B2).
The study is designed to demonstrate that PF-06801591 plus Bacillus Calmette Guerin (BCG) (induction and maintenance periods) is superior to BCG alone (induction and maintenance periods) in prolonging event free survival (EFS) in participants with high-risk naïve non-muscle invasive bladder cancer (NMIBC) and to demonstrate that PF-06801591 plus BCG (induction period only) is superior to BCG alone (induction and maintenance periods) in prolonging EFS in participants with high-risk NMIBC. The study is also designed to estimate the CR rate of PF-06801591 alone in participants with BCG unresponsive CIS and to evaluate the EFS of PF-06801591 alone in participants with BCG unresponsive NMIBC.
On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B, which enrolled participants with BCG unresponsive NMIBC. The decision to discontinue enrollment to Part B was not made for safety reasons.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85741
- Arizona Urology Specialists
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72211
- Arkansas Urology
-
-
California
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
La Jolla、California、アメリカ、92037
- Koman Family Outpatient Pavilion
-
La Jolla、California、アメリカ、92037
- Sulpizio Cardiovascular Center at UC San Diego Health
-
La Jolla、California、アメリカ、92037
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
-
Orange、California、アメリカ、92868
- University of California Irvine Medical Center
-
San Diego、California、アメリカ、92103
- UC San Diego Medical Center - Hillcrest
-
-
Colorado
-
Denver、Colorado、アメリカ、80211
- The Urology Center of Colorado
-
-
Florida
-
Hialeah、Florida、アメリカ、33016
- Urological Research Network Corp
-
Jacksonville、Florida、アメリカ、32209
- UF Health Jacksonville
-
Jacksonville、Florida、アメリカ、32218
- UF Health North
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- John H. Stroger, Jr. Hospital of Cook County
-
Lisle、Illinois、アメリカ、60532
- DuPage Medical Group
-
Lombard、Illinois、アメリカ、60148
- DuPage Medical Group Ambulatory Surgery Center
-
Lombard、Illinois、アメリカ、60148
- DuPage Medical Group
-
Naperville、Illinois、アメリカ、60540
- Edward Hospital
-
-
Louisiana
-
Shreveport、Louisiana、アメリカ、71106
- Ochsner LSU Health Shreveport - Regional Urology
-
-
Maryland
-
Hanover、Maryland、アメリカ、21076
- Chesapeake Urology Research Associates
-
-
Michigan
-
Troy、Michigan、アメリカ、48084
- Michigan Institute of Urology, PC
-
-
New York
-
New York、New York、アメリカ、10016
- Bellevue Hospital
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai
-
New York、New York、アメリカ、10016
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
New York、New York、アメリカ、10016
- NYU Langone Medical Center (Tisch Hospital)
-
New York、New York、アメリカ、10017
- NYU Langone Health Urology Associates
-
Poughkeepsie、New York、アメリカ、12603
- Premier Medical Group of the Hudson Valley PC
-
Syracuse、New York、アメリカ、13210
- Associated Medical Professionals of New York, PLLC
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center - Montefiore Medical Park
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center - Oncology Investigational Services
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- VA Portland Healthcare System
-
-
South Carolina
-
Murrells Inlet、South Carolina、アメリカ、29576
- AUC Urologists LLC
-
Myrtle Beach、South Carolina、アメリカ、29572
- Carolina Urologic Research Center
-
Myrtle Beach、South Carolina、アメリカ、29572
- Parkway Surgery Center
-
Myrtle Beach、South Carolina、アメリカ、29588.
- Atlantic Urology Clinics South Strand Office
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Baylor University Medical Center
-
Dallas、Texas、アメリカ、75231
- Urology Clinics of North Texas
-
Dallas、Texas、アメリカ、75246
- Urology Clinics of North Texas
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77027
- Houston Metro Urology
-
San Antonio、Texas、アメリカ、78229
- Urology San Antonio PA
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23507
- Sentara Norfolk General Hospital
-
Virginia Beach、Virginia、アメリカ、23462
- Urology of Virginia, PLLC
-
Virginia Beach、Virginia、アメリカ、23462
- Chesapeake Regional Surgery Center - Virginia Beach
-
-
-
-
-
London、イギリス、W6 8RF
- Charing Cross Hospital
-
London、イギリス、E1 1FR
- Barts Health NHS Trust, of Royal London Hospital
-
London、イギリス、W2 1NY
- Imperial College Healthcare NHS Trust, of The Bays, St. Mary's Hospital
-
-
CITY of London
-
London、CITY of London、イギリス、EC1A 7BE
- Barts Health NHS Trust - St. Bartholomew's Hospital
-
-
-
-
-
Arezzo、イタリア、52100
- Ospedale Area Aretina Nord - UOC Oncologia Medica
-
Arezzo、イタリア、52100
- Ospedale San Donato
-
Arezzo、イタリア、52100
- Azienda Unita Sanitaria Locale Toscana Sud-Est
-
Bari、イタリア、70124
- UO Oncologia Medica IRCCS Istituto Tumori "Giovanni Paolo II"
-
Genova、イタリア、16132
- Ospedale Policlinico San Martino, IRCCS
-
Messina、イタリア、98158
- Medical Oncology Unit, AO Papardo
-
Milan、イタリア、20132
- IRCCS Ospedale San Raffaele, URI (Urological Research Institute)
-
Province of Macerata、イタリア、62100
- Ospedale Generale Provinciale di Macerata - UOC Oncologia
-
Reggio Emilia、イタリア、42123
- AUSL/IRCCS di Reggio Emilia
-
Turin、イタリア、10128
- AO Azienda Ospedaliera Ordine Mauriziano Di Torino
-
Varese、イタリア、21100
- ASST Sette Laghi Ospedale di Circolo Fondazione Macchi
-
-
CR
-
Cremona、CR、イタリア、26100
- UO Oncologia, ASST di Cremona - Istituti Ospitalieri - Ospedale di Cremona
-
-
Catania
-
Misterobianco (CT)、Catania、イタリア、95045
- Humanitas Istituto Clinico Catanese S.p.A - U.O. Oncologia Medica
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- IRCSS Istituto Clinico Humanitas - U.O. Oncologia Medica
-
-
Other
-
Turin、Other、イタリア、10128
- Ordine Mauriziano Umberto I Hospital,
-
-
RE
-
Reggio Emilia、RE、イタリア、42122
- Azienda USL IRCCS di Reggio Emilia
-
-
-
-
New South Wales
-
Bowral、New South Wales、オーストラリア、2576
- Southern Highlands Cancer Centre
-
Camperdown、New South Wales、オーストラリア、2050
- Chris O'Brien Lifehouse Hospital
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- Box Hill Hospital
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1M9
- Vancouver Prostate Centre at the Vancouver General Hospital
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 4A6
- Hamilton Regional Laboratory Medicine Program
-
Hamilton、Ontario、カナダ、L8N 4A6
- McMaster Institute of Urology/St Joseph's Healthcare Hamilton
-
Kingston、Ontario、カナダ、K7L 3J7
- Centre for Applied Urological Research
-
Kingston、Ontario、カナダ、K7L 5G2
- Kingston Health Sciences Centre -- Hotel Dieu Hospital
-
Kingston、Ontario、カナダ、K7L 2V7
- Kingston Health Sciences Center - Queen's University
-
Toronto、Ontario、カナダ、M5G 2C4
- University Health Network
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Toronto、Ontario、カナダ、M5G 2C4
- University Health Network , Toronto General Hospital
-
-
Quebec
-
Chicoutimi、Quebec、カナダ、G7H 7K9
- Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean
-
Chicoutimi、Quebec、カナダ、G7H 5H6
- Centre integre universitaire de sante et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean
-
Montreal、Quebec、カナダ、H4A 3J1
- McGill University Health Centre
-
Montreal、Quebec、カナダ、H3H 2R9
- The Research Institute of the McGill University Health Centre
-
Québec、Quebec、カナダ、G1R 2J6
- Hotel-Dieu de Quebec - CHU de Quebec - Universite Laval
-
-
-
-
-
A Coruña、スペイン、15006
- Complejo Hospitalario Universitario A Coruna
-
Barcelona、スペイン、08025
- Fundacio Puigvert
-
Barcelona、スペイン、08003
- Hospital del Mar
-
Barcelona、スペイン、08041
- Hospital de la Santa Creu i Sant Pau
-
Cáceres、スペイン、10003
- Hospital San Pedro de Alcantara
-
Girona、スペイン、17007
- Hospital Universitari de Girona Doctor Josep Trueta
-
Llíria、スペイン、46160
- Hospital de Llíria
-
Lugo、スペイン、27003
- Hospital Universitario Lucus Augusti
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Madrid、スペイン、28006
- Hospital Universitario de La Princesa
-
Madrid、スペイン、28040
- Hospital Clínico San Carlos
-
Valencia、スペイン、46015
- Hospital Arnau de Vilanova
-
Valencia、スペイン、46009
- Fundacion Instituto Valenciano de Oncologia
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Hospital Universitari Germans Trias i Pujol
-
Granollers、Barcelona、スペイン、08402
- Hospital General de Granollers
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08907
- Hospital Universitari de Bellvitge
-
-
Madrid
-
Majadahonda、Madrid、スペイン、28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- Complejo Hospitalario de Navarra
-
-
Tarragona
-
Reus、Tarragona、スペイン、43204
- Salut Sant Joan de Reus-Baix Camp
-
-
-
-
-
Duisburg、ドイツ、47169
- Urologicum Duisburg
-
Frankfurt、ドイツ、60590
- Klinikum der Goethe-Universitaet Frankfurt
-
Münster、ドイツ、48149
- Universitaetsklinikum Muenster, Urologie
-
Nürtingen、ドイツ、72622
- Studienpraxis Urologie
-
Tübingen、ドイツ、72076
- Universitaetsklinikum Tuebingen
-
Tübingen、ドイツ、72076
- Universitaetsklinikum Tuebingen, Radiologische Universitätsklinik
-
-
-
-
-
Antony、フランス、92160
- Hôpital privé Antony (Pharmacy)
-
Antony、フランス、92160
- Hôpital Privé d'Antony
-
Bayonne、フランス、64100
- Clinique Belharra
-
Bordeaux、フランス、33000
- CHU de Bordeaux Hôpital Pellegrin
-
Bordeaux、フランス、33074
- Clinique Saint-Augustin
-
Bordeaux、フランス、33076
- Institut Bergonié
-
Brest、フランス、29200
- Cabinet Privé d'urologie
-
Brest、フランス、29200
- CHPB Keraudren
-
Brest、フランス、29229
- Groupe Vivalto Sante - Clinique Pasteur-Lanroze- CFRO
-
Limoges、フランス、87000
- Polyclinique de Limoges Site Chenieux
-
Nancy、フランス、54100
- Polyclinique de Gentilly
-
Paris、フランス、75877
- Hôpital Bichat - Claude-Bernard
-
Strasbourg、フランス、67000
- Clinique Sainte Anne
-
-
-
-
-
Ghent、ベルギー、9000
- UZ Gent
-
-
-
-
-
Gliwice、ポーランド、44-121
- NZOZ AKMED Andrzej Kupilas
-
Grudziądz、ポーランド、86-300
- Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego
-
Mysłowice、ポーランド、41-400
- Niepubliczny Zaklad Opieki Zdrowotnej Centrum Urologiczne Sp. z o.o.
-
Piotrkow Trybunalski、ポーランド、97-300
- Provita Profamilia
-
Poznan、ポーランド、60-848
- Clinical Research Center Spolka z ograniczona odpowiedzialnoscia MEDIC-R Spolka Komandytowa
-
Poznan、ポーランド、61-731
- Clinical Research Center Spolka z ograniczona odpowiedzialnoscia MEDIC-R Spolka Komandytowa
-
Skierniewice、ポーランド、96-100
- ETG Skierniewice
-
Warsaw、ポーランド、02-798
- Medical Concierge Centrum Medyczne
-
Warsaw、ポーランド、02-647
- Provita 001
-
Wroclaw、ポーランド、53-114
- Lexmedica
-
-
Łódź Voivodeship
-
Łódż、Łódź Voivodeship、ポーランド、93-513
- Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
-
-
-
-
-
Chelyabinsk、ロシア、454048
- Evimed Llc
-
Ivanovo、ロシア、153040
- Regional Budgetary Healthcare Institution "Ivanovo Regional Oncology Dispensary"
-
Kaliningrad、ロシア、236006
- Ars Medika Center, LLC
-
Kaluga、ロシア、248007
- Kaluga Regional Clinical Oncology Center
-
Moscow、ロシア、125284
- P.A. Hertsen Moscow Oncology Research Center- branch of the National Medical Research
-
Nizhny Novgorod、ロシア、603074
- Federal Budgetary Institution of Healthcare "Privolzhsky District Medical Center of the Federal
-
Nizhny Novgorod、ロシア、603001
- Federal Budgetary Institution of Healthcare "Privolzhsky District Medical Center of the Federal
-
Omsk、ロシア、644013
- BHI of Omsk region "Clinical Oncological Dispensary"
-
Ryazan、ロシア、390011
- State Budgetary Institution of Ryazan Region "Regional Clinical Oncology Center"
-
Saint Petersburg、ロシア、194017
- Federal State Budgetary Healthcare Institution Saint - Petersburg
-
Saint Petersburg、ロシア、194355
- Limited Liability Company "North-Western Medical Center"
-
Saint Petersburg、ロシア、199178
- Hospital OrKli LLC
-
Saransk、ロシア、430005
- Federal State Budgetary Educational Institution of Higher Education
-
Ufa、ロシア、450054
- Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic
-
Vologda、ロシア、160002
- Budgetary Healthcare Institution of Vologda region "Vologda Regional Clinical Hospital"
-
Vsevolozhskiy District、ロシア、188663
- Leningrad Regional Clinical Hospital
-
Yaroslavl、ロシア、150054
- SBHI YaR Regional clinical oncology hospital
-
-
Kaluga Oblast
-
Obninsk、Kaluga Oblast、ロシア、249036
- National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
-
-
Kaluzhskaya OBL.
-
Obninsk、Kaluzhskaya OBL.、ロシア、249036
- A.Tsyb Medical Research Radiological Center of the Ministry of Health of the Russian Federation
-
-
Respublika Mordoviya
-
Saransk、Respublika Mordoviya、ロシア、430032
- State Budgetary Institution of Healthcare of the Republic of Mordovia
-
-
Sankt-Peterburg
-
Pushkin、Sankt-Peterburg、ロシア、196603
- Private Medical Institution "Euromedservice"
-
-
Stavropolskiy KRAI
-
Pyatigorsk、Stavropolskiy KRAI、ロシア、357502
- Klinika UZI 4D, LLC
-
-
-
-
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Shanghai、中国、200032
- Fudan University Cancer Hospital
-
Shanghai、中国、201321
- Fudan University Shanghai Cancer Center
-
Tianjin、中国、300211
- The Second Hospital of Tianjin Medical University
-
-
Anhui
-
Hefei、Anhui、中国、230022
- The First Affiliated Hospital of Anhui Medical University
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100142
- Beijing Cancer Hospital
-
Beijing、Beijing Municipality、中国、100034
- Peking University First Hospital
-
Beijing、Beijing Municipality、中国、100730
- Peking Union Medical College Hospital
-
Beijing、Beijing Municipality、中国、100020
- Beijing Chao-yang Hospital
-
-
Fujian
-
Fuzhou、Fujian、中国、350005
- Fujian Medical University Affiliated First Hospital
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha、Hunan、中国、410013
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- Nanjing Drum Tower Hospital
-
Nantong、Jiangsu、中国、226000
- Nantong Tumor Hospital
-
Suzhou、Jiangsu、中国、215004
- Second Affiliated Hospital of Suzhou University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The First Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- First Affiliated Hospital of Xi 'an Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital of Sichuan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310014
- Zhejiang Provincial People's Hospital
-
Ningbo、Zhejiang、中国、315010
- Ningbo First Hospital
-
Wenzhou、Zhejiang、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wenzhou、Zhejiang、中国、325035
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Kagoshima、日本、890-8520
- Kagoshima University Hospital
-
Kumamoto、日本、860-0008
- National Hospital Organization Kumamoto Medical Center
-
Okayama、日本、701-1192
- Okayama Medical Center
-
Yamagata、日本、990-9585
- Yamagata University Hospital
-
-
Ehime
-
Matsuyama、Ehime、日本、791-0280
- National Hospital Organization Shikoku Cancer Center
-
Tōon、Ehime、日本、791-0295
- Ehime University Hospital
-
-
Fukuoka
-
Fukuoka、Fukuoka、日本、811-1395
- National Hospital Organization Kyushu Cancer Center
-
-
Gunma
-
Ōta、Gunma、日本、373-8550
- Gunma Prefectural Cancer Center
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、003-0804
- National Hospital Organization Hokkaido Cancer Center
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、241-8515
- Kanagawa cancer center
-
-
Osaka
-
Osaka、Osaka、日本、541-8567
- Osaka International Cancer Institute
-
Sakai、Osaka、日本、590-0197
- Kindai University Hospital
-
-
Shizuoka
-
Hamamatsu、Shizuoka、日本、431-3192
- Hamamatsu University Hospital
-
-
Tokyo
-
Shinjuku-ku、Tokyo、日本、160-8582
- Keio University Hospital
-
-
-
-
-
Daegu、韓国、41404
- Kyungpook National University Chilgok Hospital
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、03722
- Severance Hospital, Yonsei University Health System
-
Seoul、韓国、02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国、10408
- National Cancer Center
-
Seongnam-si、Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul、Seoul-teukbyeolsi [seoul]、韓国、03080
- Seoul National University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histological confirmed diagnosis of high risk non-muscle invasive transitional cell carcinoma (TCC) of the urothelium of the urinary bladder (tumors of mixed transitional/non-transitional cell histology are allowed, but TCC must be the predominant histology)
- Complete resection of all Ta/T1 papillary disease (including participants with concurrent CIS), with most recent positive TURBT occurring within 12 weeks prior to randomization or study intervention. A second TURBT must have been performed if indicated according to the current locally applicable guidelines, ie, American Urological Association, European Association of Urology
- (Cohorts B1 and B2 only): Histological confirmed diagnosis of BCG-unresponsive high-risk, non-muscle invasive TCC of the urothelium within 12 months (CIS only) or 6 months (recurrent Ta/T1 disease) of completion of adequate BCG therapy.
- Have refused or are ineligible for radical cystectomy
Exclusion Criteria:
- Evidence of muscle-invasive, locally advanced or metastatic urothelial cancer or concurrent extravesical, non-muscle invasive TCC of the urothelium
- (Cohort A only): Intravesical BCG therapy within 2 years prior to randomization. Prior intravesical chemotherapy for NMIBC is allowed.
(Cohorts B1 and B2 only): Any systemic or intravesical chemotherapy or immunotherapy from the time of most recent positive TURBT to initiation of study intervention.
- Prior immunotherapy with anti PD-1, anti PD-L1, anti PD-L2, or anti cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
- Prior treatment with immunostimulatory agents including interleukin (IL)-2, IL-15, interferon (INF)
- Prior radiation therapy to the bladder
- (Cohorts B1 and B2 only): Prior participation in Cohort A of this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:PF-06801591 + BCG induction and maintenance
PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance). |
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
他の名前:
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
他の名前:
|
|
実験的:PF-06801591 + BCG induction only
PF-06801591 in combination with Bacillus Calmette Guerin (induction only). |
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
他の名前:
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
他の名前:
|
|
アクティブコンパレータ:BCG induction and maintenance
Bacillus Calmette Guerin (induction and maintenance). |
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
他の名前:
|
|
実験的:BCG Unresponsive CIS
PF-06801591 |
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
他の名前:
|
|
実験的:BCG Unresponsive NMIBC
PF-06801591 |
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C
時間枠:From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
|
EFS: time from randomization till recurrence of high-grade disease, progression of disease, persistence of carcinoma in situ (CIS), death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after complete response (CR) for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma [Ta] or invasion into the lamina propria without invasion into the muscularis propria [T1]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis. |
From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cohort A: EFS as Assessed by the Investigator: Arm B Versus Arm C
時間枠:From randomization (Day 1) to the first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
|
EFS: time from randomization till recurrence of high-grade disease, progression of disease, CIS, death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after CR for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma [Ta] or invasion into the lamina propria without invasion into the muscularis propria [T1]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis. |
From randomization (Day 1) to the first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
|
|
Cohort A: Overall Survival (OS) for Participants: Arm A Versus Arm C
時間枠:From randomization (Day 1) until date of death due to any cause or censoring date
|
Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact |
From randomization (Day 1) until date of death due to any cause or censoring date
|
|
Cohort A: OS of Participants: Arm B Versus Arm C
時間枠:From randomization (Day 1) until date of death due to any cause or censoring date
|
Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact. |
From randomization (Day 1) until date of death due to any cause or censoring date
|
|
Cohort A: Percentage of Participants With Complete Response (CR)as Assessed by Investigator: Participants With CIS at Baseline in Full Analysis Set
時間枠:From randomization (Day 1) to the first documented CR (maximum follow up duration was up to 257.1 weeks)
|
CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. 95% CI was based on Clopper-Pearson method. |
From randomization (Day 1) to the first documented CR (maximum follow up duration was up to 257.1 weeks)
|
|
Cohort A: Duration of CR as Assessed by the Investigator: Participants With CIS at Baseline in Full Analysis Set
時間枠:From date of first documentation of CR to date of an EFS event (maximum follow up duration was up to 257.1 weeks)
|
Duration of CR was defined as the time from the first documentation of CR to the date of an EFS event for participants with CR. EFS was defined as the time in months from randomization until recurrence of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first. CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method. |
From date of first documentation of CR to date of an EFS event (maximum follow up duration was up to 257.1 weeks)
|
|
Cohort A: Time to Recurrence of Low-Grade Disease Assessed by the Investigator
時間枠:From randomization (Day 1) to the date of positive biopsy, cystoscopy or cytology results (maximum follow up duration was up to 257.1 weeks)
|
Time to recurrence of low-grade disease was defined as the time from randomization to the date of first documentation of recurrence of low-grade disease. Recurrence of low-grade disease was defined as re-appearance of low-grade disease (low-grade Ta) after randomization based on positive biopsy, cystoscopy or cytology result. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method. |
From randomization (Day 1) to the date of positive biopsy, cystoscopy or cytology results (maximum follow up duration was up to 257.1 weeks)
|
|
Cohort A: Time to Cystectomy
時間枠:From randomization (Day 1) to date of cystectomy or censoring date
|
Time to cystectomy was defined as time from randomization to cystectomy. Participants without a cystectomy will be censored at death date or last date known to be alive. |
From randomization (Day 1) to date of cystectomy or censoring date
|
|
Cohort A: Disease Specific Survival (DSS) as Assessed by the Investigator
時間枠:From randomization (Day 1) to the first documentation of death from bladder cancer
|
DSS was defined as the time from randomization to death resulting from bladder cancer, as assessed by the investigator. Participants last known to be alive will be censored at the date of last contact. |
From randomization (Day 1) to the first documentation of death from bladder cancer
|
|
Cohort A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
時間枠:From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. |
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
|
Cohort A: Number of Participants With Serious TEAEs
時間枠:From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or other events. |
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
|
Cohort A: Number of Participants With Treatment Related TEAEs and Treatment Related SAEs
時間枠:From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A SAE was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity resulted in congenital anomaly/birth defect or other events. Relatedness was based on the investigator's judgement. |
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
|
Cohort A: Number of Participant With Grade 3 or 4 and Grade 5 TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0
時間枠:From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. NCI-CTCAE version 5.0, severity was graded as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe and Grade 4 Life threatening and Grade 5: Death. |
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
|
Cohort A: Number of Participant With Laboratory Abnormalities as Based on Severity (as Graded by NCI CTCAE v5.0)
時間枠:From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
Laboratory parameters: hematocrit, hemoglobin, platelets, white blood cells, absolute neutrophil count, lymphocytes, monocytes, eosinophils, basophils, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium and bilirubin, blood urea nitrogen, urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus/phosphate, lipase, amylase, thyroid function test + reflex free thyroxine, free triiodothyronine, adrenocorticotropic hormone, international normalized ratio, partial thromboplastin time (PTT)/activated PTT, hepatitis B surface antigen, hepatitis C virus antibody. Severity grades per NCI-CTCAE v5.0: 1: Mild, 2: Moderate, 3: Severe, 4: Life threatening,5: Death. |
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy
|
|
Cohort A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Non-Muscle Invasive Bladder Cancer (QLQ-C) 30 Total Score
時間枠:Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death
|
The EORTC QLQ-C30 was a 30 self-administered questionnaire, which comprised of 5 functional domain subscales (physical functioning subscale, a role functioning subscale, an emotional functioning subscale, a cognitive functioning subscale and a social functioning subscale), 3 symptom scale (fatigue, pain, nausea and vomiting), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. All the scales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores on functional domains indicated higher levels of functioning and higher scores on symptom scale/single items indicated greater presence of symptoms. |
Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death
|
|
Cohort A: Change From Baseline in EORTC QLQ- Non-Muscle Invasive Bladder Cancer (NMIBC24) Total Score
時間枠:Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death
|
The EORTC QLQ NMIBC24 is a PRO developed and tested by the EORTC group specifically for participants with non-muscle invasive bladder cancer. The NMIBC24 has 24 items which can be grouped into 6 subscales: urinary symptoms (7 items), malaise (2 items), future worries (4 items), bloating/flatulence (2 items), sexual functioning (2 items), and male sexual issues (2 items). The NMIBC24 also assesses intravesical treatment, female sexual issues, sexual intimacy, risk of contaminating a partner, and sexual enjoyment (1 item each). All of the subscales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores indicate greater impairment, except for sexual function and sexual enjoyment items, where higher scores indicate better function. |
Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death
|
|
Cohort A: Change From Baseline in Patient Treatment Administration Burden (PTAB) Questionnaire Total Score
時間枠:Baseline up to 7 days after last dose of study treatment
|
The PTAB questionnaire was a 2-item PRO designed to assess, from the participant perspective, any pain associated with the treatment administration and the burden of the amount of time required to complete the treatment administration procedures (1 item each). The items were scored on a range of 0 to 4, where 0=no pain/ not at all burdensome and 4= extremely severe pain/ extremely burdensome. |
Baseline up to 7 days after last dose of study treatment
|
|
Cohort A: Concentration at Trough (Ctrough) of PF-06801591 for Arms A and B Only
時間枠:Pre-dose on Day 1 of Cycles 1, 2, 4, 6, 8, 10 and 13 (1 cycle=4 weeks)
|
Concentration at Trough is defined as Predose/trough concentration Observed directly from data. |
Pre-dose on Day 1 of Cycles 1, 2, 4, 6, 8, 10 and 13 (1 cycle=4 weeks)
|
|
Cohort A: Number of Participants With Positive (Anti-Drug Antibody) ADA or (Neutralizing Antibody) NAb: Arms A and B Only
時間枠:From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks and 104.4 weeks of treatment exposure for Arm A and Arm B, respectively)
|
A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had >= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a >= 4-fold dilution increase in titer from baseline in >= 1 post-treatment sample (treatment-boosted). |
From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks and 104.4 weeks of treatment exposure for Arm A and Arm B, respectively)
|
|
Cohort A: Number of Participants According to Tumor Sample Biomarker Status Based on Baseline Programmed Cell Death Ligand 1 (PD-L1) Expression
時間枠:From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks, 104.4 weeks and 110 weeks of treatment exposure for Arm A, Arm B and Arm C, respectively)
|
PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and immune cells in regions of interest that were defined by tumor cell morphology. PDL-1 status was high if >=25% tumor cell or (immune cells present in the tumor area > 1% and PD-L1 positive immune cells+ >=25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells = 100%), and low if < 25% tumor cell and [(immune cells present in the tumor area > 1% and immune cells <25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells< 100%) or immune cells present = 0]. |
From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks, 104.4 weeks and 110 weeks of treatment exposure for Arm A, Arm B and Arm C, respectively)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
一般刊行物
- Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31.
- Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.
- Shore ND, Powles TB, Bedke J, Galsky MD, Redorta JP, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary. Future Oncol. 2026 Jun;22(13):1487-1499. doi: 10.1080/14796694.2026.2671256. Epub 2026 May 24.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- B8011006
- CREST (その他の識別子:Alias Study Number)
- 2023-509089-39-00 (レジストリ識別子:CTIS (EU))
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。